论文部分内容阅读
目的探讨伊伐布雷定治疗慢性收缩性心力衰竭的临床疗效。方法 60例慢性收缩性心力衰竭患者,随机分为对照组和观察组,各30例。对照组采用常规治疗方法 ,观察组在对照组基础上采用伊伐布雷定治疗,比较两组患者的治疗效果、左心功能以及心肌生物标志物指标变化。结果观察组治疗总有效率为90%,显著高于对照组的66.67%,差异有统计学意义(P<0.05)。治疗后,观察组舒张末期左室内径(LVEDD)指标小于对照组,左室射血分数(LVEF)、每搏量(SV)指标高于对照组,差异有统计学意义(P<0.05)。观察组N端B型脑钠肽(NT-pro BNP)、胱抑素C指标显著低于对照组,差异有统计学意义(P<0.05)。结论伊伐布雷定治疗慢性收缩性心力衰竭效果显著,能够减慢心率,增强左心功能,降低心力衰竭标志物水平,具有积极的临床意义。
Objective To investigate the clinical efficacy of ivabradine in the treatment of chronic systolic heart failure. Methods Sixty patients with chronic systolic heart failure were randomly divided into control group and observation group, with 30 cases in each group. The control group was treated by conventional method. The observation group was treated with ivabradine on the basis of the control group. The therapeutic effect, left ventricular function and myocardial biomarkers were compared between the two groups. Results The total effective rate of observation group was 90%, which was significantly higher than that of control group (66.67%), the difference was statistically significant (P <0.05). After treatment, LVEDD index in the observation group was lower than that in the control group. LVEF and SV were higher in the observation group than those in the control group (P <0.05). The level of N-terminal pro-brain natriuretic peptide (BNP) and cystatin C in observation group was significantly lower than that in control group (P <0.05). Conclusion Ivabradine is effective in treating chronic systolic heart failure, which can slow heart rate, enhance left ventricular function and reduce the level of heart failure markers. It has a positive clinical significance.